Acme United Reports Third Quarter 2026 Net Sales Increase of 18%
Key Highlights
- ➤Q3 net sales $58.0 million, up 18% year over year
- ➤Q3 net income $3.4 million, up 80%; diluted EPS $0.80, up 74%
- ➤Tariff refund contributed $4.0 million to Q3 cost of goods sold
- ➤DMT facility closure accrued $1.8 million in Q3 costs
- ➤DMT closure expected to generate more than $1.0 million in annual 2027 savings
Expert Statements
Walter C. Johnsen, Chairman and CEO of Acme United Corporation
“We had record sales in the quarter, with growth in all our business units and internationally. Back-to-school sales were strong. The My Medic integration is progressing on plan, and we are beginning to receive retail and distribution commitments for its product lines next year.”
Walter C. Johnsen, Chairman and CEO of Acme United Corporation
“Transportation and many raw materials are increasing in cost. We continue to address these issues by using new robotics in our plants, sourcing very competitively, and consolidating operations. Later this year, we plan to close our DMT plant in Massachusetts and shift production and fulfillment to other locations and offshore. The annual savings from the closure are expected to be more than $1.0 million in 2027.”
Walter C. Johnsen, Chairman and CEO of Acme United Corporation
“Our balance sheet is strong, and we continue to look for acquisitions that fit our strategic criteria.”
SHELTON, Conn., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Acme United Corporation (NYSE American: ACU) today announced that net sales for the quarter ended September 30, 2026, were $58.0 million compared to $49.1 million for the same period in 2025, an increase of 18%. Excluding sales resulting from the acquisition of the assets of My Medic on January 15, 2026, comparable three-month sales increased 10%. Net sales for the nine months ended September 30, 2026, were $173.0 million, compared to $149.0 million in the same period in 2025, an increase of 16%. Excluding My Medic sales, comparable nine-month sales increased 8%.
Net income was $3.4 million, or $0.80 per diluted share, for the quarter ended September 30, 2026, compared to $1.9 million, or $0.46 per diluted share, for the same period in 2025, an increase of 80% in net income and 74% in diluted earnings per share. Net income for the nine months ended September 30, 2026, was $9.5 million, or $2.29 per diluted share, compared to $8.3 million, or $2.03 per diluted share, for the same period in 2025, an increase of 14% in net income and 13% in diluted earnings per share.
Get started
Create a free account to read the full story.